Biotech, Heart Disease, FDA
Epix Wins FDA Approval of Vasovist
Luke Timmerman 12/22/08
Epix Pharmaceuticals, a Lexington, MA-based biotech company, said today it has received FDA clearance to market gadofosveset trisodium (Vasovist) as a new contrast agent to help doctors interpret magnetic resonance scans of narrowing arteries. Epix originally asked for FDA approval in December 2003. Shares of the company (NASDAQ: EPIX) more than doubled on the news, to 83 cents at 3:41 pm Eastern.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
